Arcellx (ACLX) TD Cowen's 6th Annual Oncology Innovation Summit summary

Key data highlights

• iMMagine-1 trial data for anito-cel show a 68% complete response rate with 12.5 months median follow-up, aligning with best-in-class efficacy benchmarks like Carvykti.

• No cases of delayed neurotoxicity, Parkinsonism, cranial nerve palsies, or enterocolitis observed, distinguishing the safety profile from competitors.

• Progression-free survival (PFS) rates at 6 and 12 months are consistent with leading therapies, with data snapshots preferred over early Kaplan-Meier curves due to limited long-term follow-up.

• Data cutoff for EHA presentation matches the recent press release, with further updates expected at ASH in December, providing about five more months of follow-up.

• No exclusion of patients with peripheral neuropathy or intervention based on absolute lymphocyte count (ALC); ALC is analyzed but not used for treatment decisions.

Safety and efficacy analysis

• Safety profile is considered fundamentally different from other CAR-T therapies, with a very low probability of observing delayed neurotoxicity given current patient numbers and follow-up.

• Use of steroids and tocilizumab is consistent with prior protocols; higher steroid use in other trials did not prevent neurotoxicity, suggesting mechanism-specific safety.

• No evidence that line of therapy (fourth vs. fifth line) significantly impacts efficacy; disease characteristics like refractoriness and disease burden are more predictive.

• ALC levels are not used for intervention, and available data do not support the hypothesis that ALC above 3,000 is linked to adverse events in this context.

Regulatory and manufacturing updates

• BLA filing is targeted to enable a launch between mid and late 2026, with internal efforts focused on achieving a mid-2026 launch.

• Priority review and full approval are expected based on data strength and regulatory precedent; recent FDA leadership changes are viewed positively.

• Manufacturing tech transfer to Kite is complete, with vein-to-vein time under 17 days and 100% manufacturing success in iMMagine-3.

• Launch is expected to be differentiated by scale, availability, and reliability, leveraging Kite’s commercial footprint and manufacturing excellence.